SCHEDULE: CRISPR Therapeutics AG: Stakeholder Filing Update

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.3% stake in CRISPR Therapeutics AG as of March 31, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in significant beneficial ownership of CRISPR Therapeutics AG common stock.
• Orbis Investment Management Ltd holds 6,090,194 shares, representing 6.3% of the class.
• Allan Gray Australia Pty Ltd holds 15,817 shares, representing less than 1% of the class.
• The total combined beneficial ownership reported by both entities is 6,106,011 shares, constituting 6.3% of the class.
• The filing date for this event is March 31, 2026.
• Both Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as financial institutions (FI) equivalent to Investment Advisers (IA) and are based in Bermuda and Australia, respectively.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it solely reports on beneficial ownership changes and does not provide performance metrics or strategic insights that would indicate a positive or negative shift in the company's outlook.

Positives

• Significant institutional ownership is maintained by Orbis Investment Management Ltd, indicating continued confidence in CRISPR Therapeutics AG.
• The combined stake of 6.3% suggests a notable presence in the company's shareholder base.

Negatives

• The filing does not provide specific financial performance data or strategic updates, limiting the assessment of the company's current health.
• The information is purely related to ownership, not operational performance or future prospects.

Risks

• The filing does not explicitly mention any risks associated with the company's operations or market position.
• Potential risks could be inferred from the nature of the biotechnology industry, such as clinical trial failures, regulatory hurdles, and competitive pressures, but these are not detailed in this document.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• "Information with respect to each of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd (collectively, the "Reporting Persons") is given solely by each such Reporting Person and no Reporting Person has responsibility for the accuracy or completeness of information supplied by any other Reporting Person."
• "Notwithstanding that the Reporting Persons are making this filing together, none of the Reporting Persons represents that it is a member of a group for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended."
• "Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person as specified in Item 4(a)."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s)."
• "I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common in the biotechnology sector as institutional investors often take significant stakes in companies with high growth potential. The reported ownership by Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd reflects ongoing institutional interest in CRISPR Therapeutics AG, a key player in gene editing.

Stakeholder Impact

• Shareholders: The filing confirms significant institutional interest, which can be viewed positively as it may indicate confidence in the company's long-term prospects. However, it does not provide information on operational performance that would directly impact share value.
• Management: The filing does not contain direct commentary from CRISPR Therapeutics AG management regarding this ownership change.
• Creditors: No direct impact is indicated as the filing pertains to equity ownership.

Next Steps

• The reporting persons will continue to monitor their investment in CRISPR Therapeutics AG.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

CRISPR Therapeutics AG, Schedule 13G, Beneficial Ownership, Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, Institutional Investor, Common Stock, Securities Filing